In the study of rheumatoid arthritis (RA), considerable interest has focused on abnormalities in fibroblasts, macrophages, T cell responses, or production of T cell cytokines and/or defective control by regulatory T cells in RA that led to one of the early biologic treatments of RA, the use of anti-CD4 antibodies [1] . However, recent evaluation of the role of B cells-the youngest evolutionary immune cells-in the immune system has indicated that they are more than just the precursors of antibodysecreting cells (Table 1 ). B cells have more essential functions in regulating immune responses than had previously been realized. Therefore, it is possible that exaggeration of any of these B cell activities could contribute to the development of autoimmune disease. In this regard, B cells can function as antigen-presenting cells (Table 1) , as has been shown by animal models in which autoimmunity developed in mice that lacked secreted Ig [2••,3]. Lymphotoxin produced by B cells is essential for the differentiation of follicular dendritic cells into secondary lymphoid organs and the organization of effective lymphoid architecture [4] . In addition, antigen-presenting M cells do not develop in the gastrointestinal mucosa in the absence of B cells [5] . Similarly, activated B cells express costimulatory molecules that can be essential for the evolution of T effector cells [6] . B cells themselves may differentiate into polarized cytokine-producing effector cells that can influence the differentiation of T effector cells [7] . Most recently, interleukin (IL)-10 positive B cells with immunoregulatory functions have been identified [8] . The cytokines produced by activated B cells may influence the function of antigenpresenting dendritic cells. Taken together, these results indicate that B cells play an essential role in lymphoid organogenesis as well as in the initiation and regulation of T cell and B cell responses. Therefore, these cells represent a central component of the immune system, but they have only recently emerged as a classic therapeutic target.
Activated B cells may link the innate and adaptive immune system
From a conceptual perspective, the relation between the immunopathogenic role of the innate and adaptive immune systems in RA has regained significant interest [9,10]. There is a general perception of three stages in the course of RA: disease initiation, perpetuation, and terminal destruction process [9] [10] [11] [12] their initial concept postulating that the initiation of RA may be antigen independent by involving joint constituents. Second, the inflammatory phase appears to be driven by specific antigens-either foreign or native, and either integral to the joint or presented in the periphery. The third stage-destruction of the synovium-seems again to be antigen independent. Although the extent of B cell involvement in certain stages of the disease is not clear, their role appears to be significant, either as a link to other immune cells potentially bridging the innate and the adaptive immune systems, or as directing cellular components in inflammation ( Fig. 1 ). 
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Figure 1. Schematic role of B cells in the immunopathogenesis of rheumatoid arthritis.
Immune activation of T and B cells (A) may maintain a self-circuit by (auto)antigen and leads to activation of macrophages and fibroblasts resulting into synovitis and tissue destruction (B).
to G6PI has been suggested recently [18] . G6PI bound to the surface of cartilage as the target for anti-G6PI binding and subsequent complement-mediated damage. In this model, the inciting event is the expression of an autoreactive T cell receptor in the periphery. However, joint destruction is delegated by the adaptive response to innate immune mechanisms and can be transferred to animals that lack B cells and T cells [19] . These data initialized a potential change of the usual immune paradigm that adaptive immunity activates innate mechanisms in RA that finally account for the disabling joint destruction. Although these animal studies are very compelling and intriguing, analyses of anti-G6PI antibodies in the serum of RA patients indicate that these autoantibodies apparently do not play a significant role [20,21].
Humoral aspects and "B cell imprinting" in rheumatoid arthritis
Autoantibodies are the serologic hallmark of autoimmune diseases and serve as indicators of the break in self-tolerance. In this context, rheumatoid factor (RF) is considered to be a serologic marker in RA. A number of other autoantibodies are also present in RA, whereas the role of B cells in this disease is less clear [22-25]. Nevertheless, patients with RA who produce RF and other autoantibodies have a more severe course of the disease.
Several new antigen systems, such as antibodies against citrullinated structures with a striking specificity for RA, have been identified, demonstrating that these humoral immune disturbances are associated with a more aggressive form of RA [26] . A recent study by Baeten et al. [27] demonstrated that intracellular citrullinated proteins as well as binding of an antifillagrin antibody was confined to RA synovium, indicating a specificity and role of these autoantigenic structures in the disease. In general, the demonstration of autoantibodies against several structures in RA, including the recently identified anti-␣ enolase antibodies, indicates a higher active disease and radiologic progression, respectively, with one major exception: antibodies against IL-1 [28,29]. Although this substantiates recent strategies of blocking the effects of IL-1 in RA, the bulk of the available data demonstrate that RA patients producing autoantibodies-and therefore having a disturbed humoral homeostasis-have a more severe type of the disease.
Indications of enhanced B cell activity in rheumatoid arthritis
Indicators of an enhanced B cell activation in RA include migration into the synovium via chemokine/chemokine receptors with subsequent formation of T cell and B cell aggregates and the development of tertiary follicular structures; expression of costimulatory molecules such as the ligand for CD40 (CD154); enhanced production of several cytokines that further stimulate B cell function, including interleukin 6 (IL-6) and IL-10; markedly en-hanced mutational activity in the synovium; and abnormalities in positive and negative selection of B cells in RA [30,31,32••]. Case reports have demonstrated that mutants of both CD40 and its ligand CD154 can occur in seronegative RA and support that the induction of an appropriate immune response to self-Ig (RF) results in a more severe course of RA but does not prevent from the emergence of RA [33, 34] .
Recent studies have also focused on the characterization of the B cell phenotype under certain autoimmune conditions, including RA. In this context, an enhanced frequency of a memory B cell subgroup (CD19+/CD27+/IgD+) was found in the peripheral blood of RA patients compared with normal subjects, although differences between RA patients and normal subjects were not as striking as those identified in patients with systemic lupus erythematosus and primary Sjögren syndrome [35•,36-38] . Another study identified a predominance of CD27+ B memory cells together with a substantial number of peripheral CD27 high plasmablasts, indicating an overall higher B cell activation in RA [39] . Further longitudinal studies will evaluate the diagnostic importance of these findings. Despite these data obtained from blood B cells, recent studies characterized B cells in the inflamed synovium. One study identified CD20+/CD38− B cells from RA synovium with a dramatically reduced proliferative capacity when cultured with IL-2 and IL-10 in combination with CD40L-expressing fibroblasts [40] . The authors suggested that these cells represent a subset of effector B cells. However, there is a need to demonstrate further their impact in the pathogenesis of RA. Other studies found enhanced indications for receptor revision of the B cell receptor in RA with concomitant expression of enzymes involved in recombination [41] [42] [43] . Although there is no proof whether this reflects reexpression of recombination enzymes or recent immigrants from the bone marrow with remaining enzymatic activity, these data confirm an enhanced B cell activation in the inflamed synovium in RA.
Our understanding of the role of different B and T lymphocytes in the rheumatoid synovium has been expanded [44-46•,47]. In one study, CD4+ T cells in synovial germinal centers (GCs) were isolated by microdissection, and the activation requirements for these follicle-derived CD4+ T cells were analyzed in adoptive transfer experiments [46•]. Distinct GCs from the same patient contained identical CD4+ T cell clones that, on transfer into heterologous synovial tissues, were able to increase the production of proinflammatory mediators. Two factors were identified to be critical in determining the functional activity of follicular CD4+ T cells: matching with the MHC class II polymorphism of the implanted synovium, and the presence of B lymphocytes in the tissue. The data strongly suggest a critical role of B cells in regulating the activation of tissue-invading CD4+ T cells. Treatment of chimeric mice with anti-CD20 monoclonal antibody inhibited the production of interferon-␥ and IL-1␤, indicating that antigen presenting cells (APCs) other than B cells could not substitute in maintaining T cell activation (Fig. 1) . Given the ability of B cells to specifically capture antigen with their receptors and present it to T cells, B cells may be uniquely situated to stimulate proinflammatory T cells in rheumatoid synovitis. It is widely accepted that a specific role of MHC class II molecules is to confer susceptibility to the disease through involvement in critical antigen presentation events, either during thymic selection or in the periphery. A recent analysis demonstrated that the RAassociated HLA class II alleles DR0401, 0404, and 0405 form relatively unstable DR-CLIP (class II associated Ii peptide) complexes, whereas unrelated alleles, such as DR0402 and 0403, form long-lived complexes with CLIP [48]. The study suggested that expression of class II alleles with low affinity for CLIP may result in presentation of non-CLIP self-peptides and therefore open the possibility to break self-tolerance leading to autoimmune reactivity.
Although identification of the central autoantigen in RA is still lacking, the formation of T cell/B cell aggregates and the formation of GC-like structures may be correlated with increasing disease activity, including the production of autoantibodies, such as RF [49] . It needs to be shown whether apparent differences in the underlying pathologic process, with the disease activity likely escalating from (1) nonorganized infiltrate to (2) T cell/B cell aggregates through (3) ectopic germinal center formation. Such distinctions may indicate differences in the course of the disease that correlate B cell activity and may provide the benefit of fine-tuning therapeutic strategies, such as the decision to use conventional DMARDs, TNF blockers vs B cell depletion.
T cell-independent B cell activation: indications for the effect of established disease-modifying antirheumatic drugs
Further recent evidence indicates that B cells play an interactive role between the innate and adaptive immune systems. In detail, a study by Leadbetter et al.
[50••] could show that effective activation of RF+ B cells is mediated by IgG2a-chromatin immune complexes requiring synergistic engagement of the B cell receptor and a member of the MyD88-dependent toll-like receptor (TLR) family, likely TLR9. Bacterial and vertebrate DNAs differ by the absence of CpG methylation in bacteria. The immune system uses TLR9 to detect the presence of unmethylated CpG dinucleotides as a signal of infection; these motifs are rare in vertebrate DNA. In humans, the expression of TLR9 appears to be relatively restricted to B cells and CD123+ dendritic cells. On the detection of CpG motifs, B cells are induced to proliferate and secrete Ig, and DCs secrete a wide array of cy-tokines, interferons, and chemokines that activate T H 1 cells. Bacterial DNA or CpG motifs costimulate B cell activation through cell membrane Ig, thereby promoting the development of antigen-specific responses. This study found that immune complexes containing self-DNA activate RF-specific B cells as a result of two distinct signals: (1) engagement of the B cell antigen receptor and (2) activation of TLR9 through the DNA portion of the immune complex. Although the implications of these findings for certain autoimmune diseases need to be delineated, the evidence that TLR9 activation costimulates autoreactive B cells provides a mechanism of action for an established therapy for systemic autoimmune diseases and suggests new therapeutic approaches. Decades ago, it was found that chloroquine is an effective therapy for systemic autoimmunity, but the mechanism of its activity was not identified. Chloroquine and other compounds that interfere with endosomal acidification and maturation specifically block all the CpGmediated signals [51] . The established efficacy of hydroxychloroquine and related compounds in treating autoimmune diseases could be due to a requirement for continuous costimulation of the B cell antigen receptor and TLR9 pathways in sustaining disease activity. Moreover, it has been shown that sulfasalazine has also effects on reducing B cell activity, which further indicates that known DMARDs have the capacity to influence the biologic activity of these cells [52] .
Recent studies imply a beneficial role of depleting B cells in rheumatoid arthritis
One aspect of this review is to highlight recent advances in studying patients undergoing B cell-depleting therapies that have been possible with the availability of a humanized anti-CD20 therapy. This antibody (rituximab, RTX), initially developed as a therapy for B cell malignancies, is a humanized anti-CD20 monoclonal antibody (IgG1). It depletes B cells by complementdependent cytotoxicity and antibody-dependent cellmediated cytotoxicity. Several studies have demonstrated the beneficial effect of anti-CD20 in immune thrombocytopenia (ITP), autoimmune hemolytic anemia, cold agglutinin disease, myasthenia gravis, and Wegener granulomatosis [53] [54] [55] [56] [57] [58] [59] [60] [61] .
In RA, Edwards and Cambridge [62••] initiated an open trial of B cell depletion in five patients with refractory disease by using the humanized anti-CD20 monoclonal antibody in RA; improvement was shown in four of the five patients (Table 2) . Five patients with refractory RA were given a regimen of anti-CD20 with intravenous cyclophosphamide and high-dose steroids. All of the patients achieved responses meeting the American College of Rheumatology 50% improvement criteria (ACR-50) and 3/5 patients experienced an ACR-70 response after the first or second treatment cycle at 6 months. The use of relatively high-level immunosuppression with cyclo-phosphamide and corticosteroids in the first trial made it difficult to discern the specific contribution of B cell depletion. Subsequently, this group and other investigators pioneered further studies on the effect of anti-CD20 therapy in RA (Table 2) .
In a more recent study, the same group [63••] reported 22 patients with RA receiving five different combinations of RTX, cyclophosphamide, and/or high-dose prednisolone on an open trial basis. Although the study did not expand knowledge of the previous study and again did not allow a distinction of therapeutic effects by RTX vs cyclophosphamide vs prednisolone, the safety and major clinical improvements of this therapy were documented.
A further independent study by De Vita et al. [64••] reported the results of anti-CD20 treatment of five patients with RA that had not been responsive to combination therapy with methotrexate (MTX) and cyclosporin A, with or without anti-TNF therapy. After a washout period of 1 month, these five patients received anti-CD20 therapy alone. Four of the five patients (80%) achieved ACR-20 responses; in one of the four (20%), the response was at the ACR-50 level, and 1 (20%) had an ACR-70 response. At this point, the study by De Vita et al. [64••] confirmed the previous experiences and provided more direct evidence that B cell-ablative therapy may have a role in RA.
Very recently, Edwards et al. [65] presented data on the efficacy and safety of the first randomized placebocontrolled trial in 122 patients with RA (ACR meeting 2002, abstract 446). This study contained four treatment arms with MTX alone (n = 30), RTX alone (n = 31), RTX + cyclophosphamide (n = 31) and RTX + MTX (n = 30). Interim analysis at 24 weeks demonstrated a significant ACR-20 (80 to 84% vs 33%) and ACR-50 (45 to 50% vs 10%) response of both RTX + combination protocols vs MTX (10%) alone, whereas significant ACR-70 responses were evident only in the RTX + MTX group (23%). In this study, the monoclonal anti-CD20 antibody was reported to be well tolerated in all three treatment arms, although one patient died in the RTX + MTX group; the death was reportedly not related to the study drug. It needs emphasis that the ACR-20, ACR-50, and ACR-70 responses were overall higher than those reported in the infliximab and etanercept trials in RA but appeared to be similar to TNF blockade in ankylosing spondylitis [66] [67] [68] . A surprising result of the last study is that a combination with MTX (Յ10 mg/wk) was superior to a combination with cyclophosphamide [65] .
The studies on anti-CD20 therapy for RA provide evidence that B cells may play an important role in RA pathogenesis. However, several important questions remain to be answered until B cell depletion can be regarded as a general treatment in RA.
(1) Although most published studies documented an ACR-20 response of approximately 80%, further multicenter trials are needed to confirm efficacy and safety.
(2) Dosing of anti-CD20 in RA needs to be adjusted because several different dosages were used in almost all studies.
(3) The outcome on joint damage in patients treated with RTX, in particular radiographic changes in the long term, needs to be determined. (4) If B cell depletion is proved to be effective and safe in RA patients, therapeutic strategies are needed to guide the use of DMARDs, TNF blockers, and B cell depletion appropriately and therefore provide the best care to our patients. After all, it may be possible to use certain combinations of the available agents to obtain sufficient results. (5) One of the major side effects observed with anti-B cell therapy are airway infection. If this is confirmed, and data about the microbial spectrum emerge, rethinking of prophylaxis may be reasonable. (6) Further analysis may be required to identify the mechanism(s) by which B cell depletion works. As a potential expectation, identification of certain B cell subsets involved may provide the possibility to finetune this therapy.
Remarkably, patients who received RTX have a B cell depletion for 6 to 14 months [62-65,69•], but decreased Ig levels do not develop, and apparently they do not experience major infectious complications. Recent studies in lymphoma patients lacking an appropriate response to primary antigens, however, identified a reduced response to recall antigens in RTX treated patients [69•].
Although the role of B cells in RA has been discussed controversially and several questions remain, there is now increasing evidence for a pathogenic role of B cells in RA. On the basis of these observations, B cell ablation seems to be a further candidate as another biologic therapy in RA.
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